Guggenheim analyst Yatin Suneja initiated coverage of Praxis Precision Medicines with a Buy rating and $155 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines participates in a conference call with Truist
- Praxis Precision Medicines Shapes Future with Key Elections and Approvals
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines (NASDAQ:PRAX): A Wild Rollercoaster Ride
- Praxis Precision Medicines to Participate in Upcoming Investor Conferences